DDrare: Database of Drug Development for Rare Diseases

Abrilumab (DrugBank: Abrilumab)

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease [ 2,209 clinical trials, 1,276 drugs, (DrugBank: 240 drugs), 166 drug target genes, 210 drug target pathways]

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,209 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01696396 (ClinicalTrials.gov)	December 4, 2012	27/9/2012	Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Crohn's Disease	Crohn's Disease	Drug: Abrilumab;Drug: Placebo	Amgen	NULL	Completed	18 Years	65 Years	All	254	Phase 2	United States;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Netherlands;Switzerland;United Kingdom;Czech Republic

97. Ulcerative colitis [ 2,269 clinical trials, 1,331 drugs, (DrugBank: 241 drugs), 114 drug target genes, 181 drug target pathways]

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,269 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01694485 (ClinicalTrials.gov)	November 16, 2012	24/9/2012	Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis	A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis	Ulcerative Colitis	Biological: Abrilumab;Drug: Placebo	Amgen	NULL	Completed	18 Years	65 Years	All	359	Phase 2	United States;Australia;Austria;Belgium;Canada;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Netherlands;Norway;Poland;Russian Federation;Switzerland;United Kingdom;Czech Republic